Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Jun 15.

Published in final edited form as: Int J Cancer. 2010 Jun 15;126(12):2893–2903. doi: 10.1002/ijc.24995

(a) AU565 breast cancer cells were incubated with lapatinib, HER2-vaccine induced antibodies, LacZ-vaccine induced antibodies, and trastuzumab with or without lapatinib. Lysates were analyzed by Western blot for HER2, pztyr (all phosphorylated tyrosines), ERK1/2, pERK, pAKT, AKT1/2, and survivin. Vaccine induced antibodies were used at a dilution of 1:50; lapatinib was at 0.1 μM; and trastuzumab was at 10 μg/ml. (b) Au565 cells (1 × 10⁴) cells were treated with vaccine induced antibodies (1:50 dilution) with or without lapatinib (0.1 μM) for 3 days. Live cells were measured using a thiazolyl blue (MTT) cell proliferation assay by reading A⁴⁸⁵ and the mean percent inhibition of proliferation +/− standard deviation (SD) is represented. All treatments were performed in triplicate.

(a) AU565 breast cancer cells were incubated with lapatinib, HER2-vaccine induced antibodies, LacZ-vaccine induced antibodies, and trastuzumab with or without lapatinib. Lysates were analyzed by Western blot for HER2, pztyr (all phosphorylated tyrosines), ERK1/2, pERK, pAKT, AKT1/2, and survivin. Vaccine induced antibodies were used at a dilution of 1:50; lapatinib was at 0.1 μM; and trastuzumab was at 10 μg/ml. (b) Au565 cells (1 × 10⁴) cells were treated with vaccine induced antibodies (1:50 dilution) with or without lapatinib (0.1 μM) for 3 days. Live cells were measured using a thiazolyl blue (MTT) cell proliferation assay by reading A⁴⁸⁵ and the mean percent inhibition of proliferation +/− standard deviation (SD) is represented. All treatments were performed in triplicate.